MUC1

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

Retrieved on: 
Tuesday, December 6, 2022
Therapy, BCMA, Security (finance), Oncology, European Society for Medical Oncology, Lung, Therapeutic index, B-cell maturation antigen, MUC1, Diagnosis, Epithelium, Patient, University of Maryland Medical Center, Cancer, Degenerative disease, Toxicity, Assistant professor, Roche, Breast cancer, GVHD, Safety, RRMM, University of California, ESMO, Efficacy, Multimedia, Infrared spectroscopy correlation table, University, Breast, Cytokine release syndrome, SAN, CRS, Febrile neutropenia, Vaccine, Pharmaceutical industry, Medical imaging, Risk management, Takeda

SAN DIEGO, Dec. 6, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Key Points: 
  • "While it is still quite early in both trials, we have seen encouraging responses in both P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the lowest doses as well as favorable tolerability.
  • Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both breast and ovarian cancer.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

Retrieved on: 
Thursday, November 10, 2022
GLOBE, YouTube, Private Securities Litigation Reform Act, Forward-looking statement, Code, Tumor microenvironment, Euronext Growth, Annual general meeting, Immunotherapy, Cancer, Technology, U.S. Securities and Exchange Commission, CAR, Annual report, MUC1, NASDAQ, TNBC, Safety, CART, Survival, Gene editing, Senior, Cell engineering, Nasdaq, Patient, Immune system, TME, Social media, TGFBR2, Securities & Exchange Commission of Pakistan, Society, TS, SITC, Triple-negative breast cancer, Vaccine, Medical imaging, Office supplies, Mobile phone, Cellectis

The poster presentations highlight the following preclinical data:

Key Points: 
  • The poster presentations highlight the following preclinical data:
    This poster highlights TALEN-edited smart CAR T-cells targeting MUC1- expressing solid tumors.
  • MUC-1 CAR T-cells infiltrate tumors more efficiently and extend survival when enhanced with attributes catered towards the tumor microenvironment (TME) of TNBC tumors.
  • Enhanced MUC-1 CAR T-cells could address some of the current challenges in development of CAR Ts for TNBC patients with unmet medical needs.
  • Overall, we can efficiently generate allogeneic CAR T-cells and engineer them to overcome several key challenges of immune suppressive solid tumors.

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

Retrieved on: 
Thursday, November 3, 2022
Security (finance), Safety, Oncology, SAN, ESMO, RRMM, U.S. Securities and Exchange Commission, Transposase, European Society for Medical Oncology, B-cell maturation antigen, Neoplasm, Genetic engineering, MUC1, 2021 Essex County Council election, Cancer, Private Securities Litigation Reform Act, Efficacy, BCMA, Patient, Epithelium, Breast, Relapse, Therapy, Multiple myeloma, Lung, Roche, Multimedia, Nasdaq, AAV, Vaccine

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Key Points: 
  • SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.
  • The full abstracts will be made available on the ESMO website on December 1, 2022 at 12:05 AM CET.
  • Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both breast and ovarian cancer.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Monday, October 17, 2022
American Association for Cancer Research, Lung, Infection, Colon, Communication, Therapy, SEC, Head, Review, Conference, MUC1, AML, Vaccine, Neck, Neoplasm, Patient, Vulvar cancer, Research, Twitter, Cancer, Immunotherapy, Nasdaq, Risk, Technology, Hepatitis C alternative reading frame stem-loop, Goal, Immune system, Company, AACR, Prostate, Alternative, TARP, PDSB, American Association, Nature, GLOBE, Forward-looking statement, Peptide, PDS, COVID-19, Biotechnology, Breast, Pharmaceutical industry

The AACR Tumor Immunology and Immunotherapy Conference is being held October 21-24, 2022, in Boston.

Key Points: 
  • The AACR Tumor Immunology and Immunotherapy Conference is being held October 21-24, 2022, in Boston.
  • Versamune is PDS Biotechs novel investigational T cell activating platform designed to stimulate a precise immune system response to cancer-specific proteins.
  • The research accepted for presentation at the AACR Tumor Immunology and Immunotherapy Conference highlights this important versatility of the platform and, specifically, the rationale for our PDS0102 and PDS0103 programs, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech.
  • Versamune is a registered trademark and Infectimune is a trademark of PDS Biotechnology.

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Cancer, LinkedIn, Triple-negative breast cancer, MUC1, Euronext Growth, SITC, YouTube, Annual report, NASDAQ, Patient, Gene editing, Nasdaq, Immunotherapy, CAR, Technology, Private Securities Litigation Reform Act, Immune system, U.S. Securities and Exchange Commission, TNBC, Society, Thomas Jefferson National Accelerator Facility, Securities & Exchange Commission of Pakistan, Social media, 2021 Essex County Council election, GLOBE, EST, Forward-looking statement, ISCB Senior Scientist Award, Vaccine, Flour, Cellectis

Cellectis will present a poster on TALEN-edited smart CAR T-cells targeting MUC1- expressing solid tumors.

Key Points: 
  • Cellectis will present a poster on TALEN-edited smart CAR T-cells targeting MUC1- expressing solid tumors.
  • MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.
  • Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies.
  • These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management.

PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022

Retrieved on: 
Tuesday, September 13, 2022
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Science, Oncology, MUC1, Safety, Memory, Blood bank, RNA transfection, Bioreactor, Hlas, Hope, Data monitoring committee, KU Leuven, Population, European Society for Medical Oncology, Growth, Progression-free survival, NY-ESO-1, Melanoma, MAGE, Lung cancer, Patient, Degenerative disease, RECIST, CEO, Dendritic cell, Technology, Oncology, DLT, Large-cell lung carcinoma, SAE, PDC, EFS, PD-L1, PD-1, Mutation, Cancer, PBMC, GMP, B cell, Non-small-cell lung carcinoma, ESMO, Pharmaceutical industry, Vaccine, A2, NSCLC, A1

The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated with, or not, anti-PD-1 treatment in NSCLC patients.
  • Results are reported on the first three cohorts that have been completed (A1/A2/B1).
  • With preliminary clinical data now available from patients of the first three enrolled cohorts, it is encouraging to see PDC*lung01 as safe, immunogenic and to have signs of clinical efficacy.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

Retrieved on: 
Tuesday, May 24, 2022
Cancer, Breast, Colon, Zika virus, Form, Company, Immunotherapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Infection, Neoplasm, GeoVax, Nasdaq, Method, Prostate, Patient, Vaccine, Cyclin B1, Virus-like particle, Ovary, Tumor-associated macrophage, COVID-19, Vaccination, Research, Patent, FDA, MUC1, IND, Biotechnology, Intellectual property, Antigen, Immunodeficiency, Human, University, Technology, Risk, Lung, Head, MVA, 1836 U.S. Patent Office fire, SEC, Malaria, University of North Carolina at Greensboro, CEO

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the Chinese Patent Office has issued a Notice of Allowance for GeoVax’s patent application titled “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen.”

Key Points: 
  • GeoVax believes that its MVA vector platform is well-suited for development of therapeutic cancer vaccines based on the expression of tumor-associated antigens such as MUC1 and Cyclin B1.
  • David Dodd, GeoVax President and CEO, commented, This patent allowance complements the previously issued U.S. Patent No.
  • GeoVax is committed to advancing meaningful cancer immunotherapies towards improving the lives of patients worldwide.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms.

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Retrieved on: 
Thursday, March 24, 2022
Company, Cancer, MUC1, Daiichi Sankyo, Therapy, Sale, Lung, Neck, Kidney, ADC, Squamous cell carcinoma, Colorectal cancer, Primary tumor, LYPD3, CAR, Ley, Biotechnology, Research, Head, Antigen, Mab, Ovarian cancer, Breast, Control, Canadian Aviation Regulations, HNSCC, Immunoglobulin G, Drug discovery, CD174, Research and development, Protein, Patient, Large-cell lung carcinoma, Antibody, Vaccine, Fine chemical, Medical imaging

The Company has also expanded its senior leadership team to accelerate the execution and delivery of this strategy.

Key Points: 
  • The Company has also expanded its senior leadership team to accelerate the execution and delivery of this strategy.
  • Following the recent spin-out of its services business Glycotope is now entirely focused on drug discovery and development, utilizing its proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • As a result of this shift in strategy and to optimize its delivery, the Company has undertaken an expansion of its senior leadership roles.
  • Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-target/off tumor toxicity, key elements of highly potent therapies.